Breast Cancer - Data Show Synergistic Activity Of Telomerase Inhibitor Drug And Trast

[News]

Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, GRN163L, significantly boosts the effects of trastuzumab (Herceptin?) against HER2-positive breast cancer cells and restores sensitivity to trastuzumab in trastuzumab resistant tumor cells. The research published online yesterday in Breast Cancer Research and Treatment was conducted by Dr.

More... (http://www.medicalnewstoday.com/articles/125724.php)